Dicerna Pharma (DRNA) Tops Q1 EPS by 2c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Nasdaq ends higher as AI heavyweights rebound ahead of midterm results
- Apple shares slip amid guidance for tightening margins, slowing services growth
- Rising shorts cool U.S. large-cap positioning, cutting liquidation risk: Citi
- Apple's 'unprecedented' memory warning adds fuel to wobbly Micron, SK hynix trade
- Palantir raises 2026 revenue outlook after quarterly revenue nearly doubles on AI
Tweet
Share
E-mailGet Alerts DRNA Hot Sheet
Join SI Premium – FREE
Dicerna Pharma (NASDAQ: DRNA) reported Q1 EPS of ($0.68), $0.02 better than the analyst estimate of ($0.70). Revenue for the quarter came in at $133 thousand versus the consensus estimate of $20 thousand.
Guidance
With the closing of its Preferred Stock transaction, Dicerna believes that it has sufficient cash to fund the execution of its current operating plan into 2019, which includes focusing its resources on advancing its first three development programs into proof of concept studies and a fourth program into formal preclinical development. This estimate assumes no additional funding from new partnership agreements or from additional financing events.
For earnings history and earnings-related data on Dicerna Pharma (DRNA) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Latham Group, Inc. (SWIM) Misses Q3 EPS by 5c ; Offers Guidance
- Bowhead Specialty Holdings (BOW) Tops Q3 EPS by 54c
- Lime Energy (LIME) Reports Q3 EPS of $0.63 ; Offers Guidance
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
